Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 3Sarcoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neoplasm Metastasis 2Gliosarcoma 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Astrocytoma 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Glioma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1

Interventions

fludarabine phosphate 6Cytarabine 6Peripheral Blood Stem Cell Transplantation 4Etoposide 4Busulfan 4Hydroxyurea 3Filgrastim 3Decitabine 3Cyclophosphamide 3romidepsin 2laromustine 2Vorinostat 2Tretinoin 2Sunitinib 2Radiotherapy 2Methotrexate 2Ipilimumab 2Idarubicin 2Daunorubicin 2CTLA-4 Antigen 2Antilymphocyte Serum 2Analgesia 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2veliparib 1valspodar 1tipifarnib 1perifosine 1gamma-Globulins 1belinostat 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × aflibercept × Clear all
NCT00509249 2015-01-08

Aflibercept in Treating Patients With Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2 Terminated
18 enrolled 4 charts
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡